华康生物医学2025 中期报告

(incorporated in the Cayman Islands with limited liability)Stock Code: 8622 2025INTERIM REPORT CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OFHONG KONG LIMITED (THE “STOCK EXCHANGE”)GEM GEM has been positioned as a market designed to accommodate small and mid-sized companies towhich a higher investment risk may be attached than other companies listed on the Stock Exchange.Prospective investors should be aware of the potential risks of investing in such companies and shouldmake the decision to invest only after due and careful consideration. Given that the companies listed on GEM are generally small and mid-sized companies, there is a riskthat securities traded on GEM may be more susceptible to high market volatility than securities tradedon the Main Board of the Stock Exchange and no assurance is given that there will be a liquid market inthe securities traded on GEM. Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of thisreport (“Report”), make no representation as to its accuracy or completeness and expressly disclaim any liabilitywhatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of theReport. This Report, for which the directors (the “Directors”) of Huakang Biomedical Holdings Company Limited (the“Company”, and together with its subsidiaries, the “Group”, “we” or “our”) collectively and individually acceptfull responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities onGEM of the Stock Exchange (the “GEM Listing Rules”) for the purpose of giving information with regard tothe Group. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledgeand belief, the information contained in this Report is accurate and complete in all material respects and notmisleading or deceptive, and there are no other matters the omission of which would make any statement hereinor this Report misleading. GEM GEMGEMGEM GEMGEM CONTENTS Corporate Information3Management Discussion and Analysis5Other Information17Unaudited Condensed ConsolidatedStatement of Profit or Loss andOther Comprehensive Income25Unaudited Condensed ConsolidatedStatement of Financial Position27Unaudited Condensed ConsolidatedStatement of Changes in Equity29Unaudited Condensed ConsolidatedStatement of Cash Flows30Notes to the Unaudited CondensedConsolidated Financial Statements31 CORPORATE INFORMATION Ms. Chow Ching Man (resignedon 22 January 2025)Ms. Shih Mei Ling (resigned on28 February 2025)Dr. Cheng Faat Ting Gary(resigned on 8 July 2025) Board of Directors Remuneration Committee Ms. Wang Yachun(Chairman)(appointed on 30 June 2025)Dr. Chow Kwok Fai JosephMr. Zhang ChunguangDr. Cheng Faat Ting Gary(resigned on 8 July 2025) Executive DirectorsMr. Zhang Shuguang(Chairman)Mr. Zhang ChunguangMr. Poon Lai Yin MichaelMs. Zhang Yujing (appointed on16 April 2025)Mr. He Jiaming (resigned on16 April 2025) Audit Committee Mr. Tsui Wing Tak(Chairman)(appointed on 22 January2025)Dr. Chow Kwok Fai JosephMs. Wang Yachun (appointedon 30 June 2025)Ms. Chow Ching Man (resignedon 22 January 2025)Dr. Cheng Faat Ting Gary(resigned on 8 July 2025) Nomination Committee Mr. Zhang Shuguang(Chairman)Dr. Chow Kwok Fai JosephMs. Wang Yachun (appointedon 30 June 2025)Ms. Chow Ching Man (resignedon 22 January 2025) Non-executive DirectorsDr. Bu SuDr. Xu Ming Independent Non-executiveDirectorsDr. Chow Kwok Fai JosephMr. Tsui Wing Tak (appointed on22 January 2025)Ms. Wang Yachun (appointedon 30 June 2025) Company Secretary Mr. Chau Lai Ki CORPORATE INFORMATION Principal Place of Businessin Hong Kong Principal Share Registrarand Transfer Office in theCayman Islands AuthorisedRepresentatives (for thePurposes of the GEMListing Rules)GEM Room 04, 9 FloorKimberley House35–35A Kimberley RoadTsim Sha TsuiKowloonHong Kong35–35A904 Conyers Trust Company(Cayman) LimitedCricket SquareHutchins DriveP.O. Box 2681Grand Cayman, KY1-1111Cayman Islands Mr. Zhang ShuguangMr. Poon Lai Yin Michael Compliance Officer Hong Kong ShareRegistrar and TransferBranch Office Mr. Poon Lai Yin Michael Principal Place of Businessin the PRC Legal Advisers as to HongKong Laws Tricor Investor Services Limited17/F., Far East Finance Centre16 Harcourt RoadHong Kong1617 1–3/F and 5/F, Building DShenzhen JunxuanNo. 16 Yinkui RoadKui Xin CommunityKui Chong OfficeDapeng New DistrictShenzhenThe PRC16D Tung, Ng, Tse & Lam Solicitors Auditor Forvis Mazars CPA Limited Company’s Websitehttp://www.huakangbiomedical.com Registered Office Stock Code Cricket SquareHutchins DriveP.O. Box 2681Grand Cayman, KY1-1111Cayman Islands 8622 MANAGEMENT DISCUSSION AND ANALYSIS BUSINESS REVIEW The shares of the Company (the “Shares”) were listedon GEM of the Stock Exchange (the “Listing”) on 13December 2018 (the “Listing Date”) by way of shareoffer (“Share Offer”). GEM Biological Reagents and Auxiliary Re